KILIÇKAP, S. Et Al. 2018. The efficacy and safety of crizotinib in patients with ROS1 positiveadvanced stage NSCLC: The real-world experience from Turkey. ESMO 2018 , (Munich, Germany).

KILIÇKAP, S., ÖLMEZ, Ö. F., ÇİÇİN, İ., DEMİRCİ, U., ALAN, Ö., ÇABUK, D., ... ŞAKALAR, T.(2018). The efficacy and safety of crizotinib in patients with ROS1 positiveadvanced stage NSCLC: The real-world experience from Turkey . ESMO 2018, Munich, Germany

KILIÇKAP, SAADETTİN Et Al. "The efficacy and safety of crizotinib in patients with ROS1 positiveadvanced stage NSCLC: The real-world experience from Turkey," ESMO 2018, Munich, Germany, 2018

KILIÇKAP, SAADETTİN Et Al. "The efficacy and safety of crizotinib in patients with ROS1 positiveadvanced stage NSCLC: The real-world experience from Turkey." ESMO 2018 , Munich, Germany, 2018

KILIÇKAP, S. Et Al. (2018) . "The efficacy and safety of crizotinib in patients with ROS1 positiveadvanced stage NSCLC: The real-world experience from Turkey." ESMO 2018 , Munich, Germany.

@conferencepaper{conferencepaper, author={SAADETTİN KILIÇKAP Et Al. }, title={The efficacy and safety of crizotinib in patients with ROS1 positiveadvanced stage NSCLC: The real-world experience from Turkey}, congress name={ESMO 2018}, city={Munich}, country={Germany}, year={2018}}